These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Parkinson's disease. Clarke CE; Moore AP Am Fam Physician; 2007 Apr; 75(7):1045-8. PubMed ID: 17427619 [No Abstract] [Full Text] [Related]
6. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Brefel-Courbon C; Payoux P; Thalamas C; Ory F; Quelven I; Chollet F; Montastruc JL; Rascol O Mov Disord; 2005 Dec; 20(12):1557-63. PubMed ID: 16078219 [TBL] [Abstract][Full Text] [Related]
7. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of cerebral vasomotor reactivity in Parkinson's disease: is there any association with orthostatic hypotension? Zamani B; Mehrabani M; Fereshtehnejad SM; Rohani M Clin Neurol Neurosurg; 2011 Jun; 113(5):368-72. PubMed ID: 21247685 [TBL] [Abstract][Full Text] [Related]
9. Does levodopa therapy delay death in Parkinson's disease? Uitti RJ; Ahlskog JE; Maraganore DM Mov Disord; 1996 May; 11(3):343-4. PubMed ID: 8723162 [No Abstract] [Full Text] [Related]
10. Deep brain stimulation for Parkinson's disease. Med Lett Drugs Ther; 2009 Apr; 51(1309):26-7. PubMed ID: 19343007 [No Abstract] [Full Text] [Related]
11. [Disturbance of micturition in Parkinson's disease]. Sakakibara R; Uchiyama T; Yoshiyama M; Hattori T No To Shinkei; 2001 Nov; 53(11):1009-14. PubMed ID: 11761908 [No Abstract] [Full Text] [Related]
12. The variability of levodopa response in Parkinson's disease: is sensitization reversible? Jabre MG; Bejjani BP Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452 [No Abstract] [Full Text] [Related]
13. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339 [TBL] [Abstract][Full Text] [Related]
14. The effects of levodopa on word intelligibility in Parkinson's disease. De Letter M; Santens P; Van Borsel J J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723 [TBL] [Abstract][Full Text] [Related]
15. Does levodopa affect metaiodobenzylguanidine myocardial accumulation in Parkinson's disease? Kishi M; Sakakibara R; Terada H; Ogawa E; Tateno T Mov Disord; 2011 Feb; 26(3):563-4. PubMed ID: 21287597 [No Abstract] [Full Text] [Related]
16. Deprenyl and levodopa and Parkinson's disease progression. Fowler JS; Fazzini E; Volkow ND Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616 [No Abstract] [Full Text] [Related]
17. [Drug therapy in Parkinson's disease]. van Hilten JJ; Roos RA Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151 [TBL] [Abstract][Full Text] [Related]
18. [Pergolide: a useful agonist for the treatment of Parkinson disease]. Bonnet AM; Houeto JL Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908 [TBL] [Abstract][Full Text] [Related]
19. Does thalamotomy alter the course of Parkinson's disease? Tasker RR; DeCarvalho GC; Li CS; Kestle JR Adv Neurol; 1996; 69():563-83. PubMed ID: 8615182 [No Abstract] [Full Text] [Related]
20. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality. Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764 [No Abstract] [Full Text] [Related] [Next] [New Search]